Key Takeaways:
InnoCare Pharma reported a 607.7% year-over-year surge in first-quarter net profit, though the biotech firm’s shares fell on the news.
"We maintained strong growth momentum in the first quarter of 2026, with enhanced market penetration, accelerated globalization, and breakthroughs across multiple pipelines," Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, said in a statement.
The Beijing-based company’s net profit reached RMB 102.4 million for the three months ending March 31, according to a company press release. Total revenue increased by 38.7% to RMB 528.6 million, while drug sales alone jumped 44.5% to RMB 450.5 million. The results build on the company’s first full year of profitability achieved in 2025.
Despite the robust growth figures that continued from the previous year, InnoCare’s Hong Kong-listed shares (09969.HK) dropped 5.3% during trading on April 23. The negative market reaction suggests investors may have anticipated even stronger results or could be concerned about the sustainability of its growth trajectory against competitors like BeiGene (6160.HK).
The company's revenue growth was primarily fueled by the expanded commercialization of its core drug, orelabrutinib. Sales of the BTK inhibitor have grown rapidly since its new indication for first-line chronic lymphocytic leukemia was included in China's National Reimbursement Drug List (NRDL).
InnoCare is also beginning to see sales contributions from two other recently approved drugs: the CD19 antibody tafasitamab, for treating diffuse large B-cell lymphoma, and the next-generation TRK inhibitor zurletrectinib.
InnoCare increased its research and development spending by 10.4% year-over-year to RMB 229.2 million in the quarter. The company highlighted increased investment in new technology platforms such as antibody-drug conjugates (ADCs) and molecular glue, areas with heavy competition and high potential. The company maintains a strong cash position with approximately RMB 7.9 billion in cash and related accounts to support its global clinical development.
The strong earnings report follows the removal of the special "U" designation from the company's STAR market ticker in March, a mark given to unprofitable companies. The removal signaled InnoCare's entry into a phase of more sustainable development. However, the subsequent share price drop indicates the market may be pricing in higher future expectations. Investors will be watching the company's semi-annual results in August for signs of continued sales momentum.
This article is for informational purposes only and does not constitute investment advice.
